Ingredion Inc (INGR) stock intrinsic value fair value estimate & owner earnings analysis

Ingredion turns corn, tapioca, stevia and other plant materials into starches, sweeteners and specialty ingredients for food, beverage, animal nutrition, brewing and industrial customers. It reports three segments. Texture & Healthful Solutions (specialty texturizers and clean-label starches) earned $405 million of operating income in 2025, up 16%. Food & Industrial Ingredients LATAM earned $493 million. Food & Industrial Ingredients U.S./Canada earned $315 million, down 16% on lower volumes and production problems at a large plant. What changed. Two events reshape the company since our earlier estimate. On June 30, 2026 it sold 51% of its Pakistan business, which had about $250 million of sales and $35 million of operating income in 2025, for $165 million and kept a 20% stake. On June 8, 2026 it agreed to acquire Tate & Lyle, the UK specialty ingredients company, for 595 pence a share in cash. That is about $3.5 billion for the equity, or roughly $4.75 billion including Tate & Lyle's £939 million of net debt. Tate & Lyle shareholders have approved the deal, and completion is expected in the second half of 2027, subject to regulatory and court approvals. Our earlier figures did not reflect the acquisition, which is now the largest single item in the valuation. How we measure earnings. We start from the cash Ingredion's operations produce. We remove timing swings in inventory and receivables, charge stock compensation as a real cost, and deduct all capital spending. Because revenue was falling in 2024-2025, we treat all of it as the cost of staying in business. We then add back interest, so the business is valued first and debt is subtracted separately. On that basis the business produced $434-478 million a year in 2018-2021 and $625-753 million a year in 2022-2025, with a median of $665 million. The Pakistan sale removes an estimated $15 million a year of Ingredion's share. One judgement matters. Capital spending was $433 million in 2025, against $284-350 million in every year from 2016 to 2024. The company has committed $400-440 million for 2026 and describes the spending as updating, expanding and improving its facilities. We assume part of that step-up is permanent, which puts normal earning power at about $620 million a year. Recent results. The first half of 2026 was weak. Operating income fell to $391 million from $547 million, including $53 million of acquisition costs and $56 million of restructuring and impairment charges. Second-quarter gross margin fell to 23% from 26%, and operating cash flow fell to $123 million from $262 million. The company reported that production rates at its Argo plant were restored by the end of the second quarter. Business cash flow fell 5% in 2025. Base case. Business cash flow of $575 million for the coming year, about 11% below 2025's $648 million (partly the Pakistan sale). It then rises to $600 million, then holds flat at $620 million, the level the business has already earned under its current shape. We credit no growth: the specialty volume gains, the $130 million synergy target for Tate & Lyle and share repurchases are not secured. Because these are everyday ingredients made in hard-to-replicate wet-milling plants, we assume earning power continues beyond ten years. Tate & Lyle is valued on its own cash flows. For the year to March 2026 its audited operating cash flow was £230 million after £50 million of interest and £29 million of tax. Adding back interest and a £43 million working-capital build, and deducting £8 million of share-based pay and £125 million of capital spending, gives about £190 million before lenders. Adding back £39 million of one-off integration spending and charging a normal tax bill gives about £200 million, or roughly $265 million a year. Its revenue fell 3% that year at constant currency. Held flat, that stream is worth about $4.17 billion today, against a purchase price of about $4.48 billion in today's money. In total, the business is worth about $14.44 billion: $10.27 billion for Ingredion alone and $4.17 billion for Tate & Lyle. It owes about $5.51 billion. That is $1.03 billion of net debt today plus $4.48 billion for Tate & Lyle. The net debt figure is $1.78 billion of borrowings, less about $0.60 billion of cash beyond operating needs, less about $0.15 billion because $1 billion of notes is fixed at 2.9-3.9% for years. That leaves $8.93 billion, or about $139.71 a share. Without the acquisition, the base case would be about $145. Bear case (roughly a one-in-ten outcome). Ingredion earns $520 million next year, then repeats its 2018-2021 stretch for three years at about $440 million a year. In that stretch, operating income fell from $836 million in 2017 to $582 million in 2020. It then recovers only to $540 million a year, because the higher capital spending proves permanent. Tate & Lyle earns about $200 million a year. The $175 million cost of combining the companies is spent without the synergies arriving. The revolving credit agreement caps leverage at 3.5 times, and the company expects about 3 times at completion, so a trough soon after closing would press that limit. We charge an extra percentage point on the acquisition borrowing for three years. The business is worth about $11.87 billion and owes about $5.79 billion, leaving $6.09 billion, or about $95.24 a share. Even at the trough, business cash flow covers estimated interest roughly twice. Bull case (roughly a one-in-ten better outcome). The Argo plant stays fixed and capital spending returns toward its 2016-2024 range after the 2026 commitments. Business cash flow rises to $600 million, then $660 million, then $690 million, in line with 2023-2024. Tate & Lyle's revenue returns to its prior-year level of £2,124 million, lifting its cash flow to about $295 million. The business is worth about $16.03 billion and owes about $5.51 billion, leaving about $164.55 a share. The margin-of-safety price. The earnings level of Ingredion alone is well documented: ten years of filings show a range of $434-753 million. Adding Tate & Lyle, a business whose sales fell last year and whose returns on capital are lower, widens the range of outcomes. The worst plausible outcome is a repeat of 2018-2021 arriving just after the acquisition closes, when debt peaks near the covenant limit. The structure would survive it: business cash flow would still cover interest about twice, the assets are hard plants serving staple demand, and no single customer dominates. The dividend and share repurchases, however, could be squeezed. The things we are most likely to be wrong about are whether the higher capital spending is permanent and what Tate & Lyle earns under new ownership. If only Tate & Lyle disappoints, the shares are worth about $124. If only the capital spending is permanent, they are worth about $125. If both happen, they are worth about $109. The company pays $3.28 a year in dividends during the holding period. The margin-of-safety price is $85. It assumes a three-year holding period. From $85, the base case implies roughly 21% a year including dividends, and the bear case implies roughly 7% a year.